FAISAL MUSA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- DEARBORN, MI
- NPI
- 1811138787
- Received
- $975,683 in 1,309 records, 2019 to 2025
- As principal investigator
- $658,153 of research payments to others in 24 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 138 | $85,766 |
| 2024 | General payment | 335 | $228,950 |
| 2023 | General payment | 285 | $202,382 |
| 2022 | General payment | 192 | $158,217 |
| 2021 | General payment | 185 | $157,399 |
| 2020 | General payment | 28 | $16,639 |
| 2019 | General payment | 146 | $126,327 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 225 | $720,550 |
| Travel and Lodging | 531 | $142,325 |
| Consulting Fee | 39 | $65,784 |
| Food and Beverage | 483 | $23,736 |
| Honoraria | 13 | $22,277 |
| Long term medical supply or device loan | 8 | $732 |
| Education | 10 | $277 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Daiichi Sankyo Inc. | $97 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-12-16 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-12-11 | E.R. Squibb & Sons, L.L.C. | $109 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-25 | AstraZeneca Pharmaceuticals LP | $344 | Travel and Lodging | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-11-25 | GlaxoSmithKline, LLC. | $28 | Food and Beverage | In-kind items and services | BLENREP Biological, ONCOLOGY | 2025 | |
| 2025-11-25 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-11-18 | Geron Corporation | $2,560 | Consulting Fee | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-11-18 | Geron Corporation | $50 | Travel and Lodging | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-11-18 | Geron Corporation | $44 | Travel and Lodging | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | Syndax Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-28 | Takeda Pharmaceuticals U.S.A., Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Daiichi Sankyo Inc. | $51 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-28 | Daiichi Sankyo Inc. | $10 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-27 | Daiichi Sankyo Inc. | $502 | Consulting Fee | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $922 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $47 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $44 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $8 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-23 | Axsome Therapeutics, Inc. | $110 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-18 | Geron Corporation | $71 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-18 | Geron Corporation | $50 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-18 | Geron Corporation | $40 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-18 | Geron Corporation | $25 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $53 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $44 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $8 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $4 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-15 | Daiichi Sankyo Inc. | $4,690 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-15 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $91 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-09 | Daiichi Sankyo Inc. | $125 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-06 | Exelixis Inc. | $15 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-10-04 | Regeneron Healthcare Solutions, Inc. | $3,954 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $295 | Travel and Lodging | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $5 | Food and Beverage (4 payments) | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $3 | Travel and Lodging | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-29 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-09-26 | Regeneron Healthcare Solutions, Inc. | $100 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $5,272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-22 | Regeneron Healthcare Solutions, Inc. | $383 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-22 | Regeneron Healthcare Solutions, Inc. | $255 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-22 | Regeneron Healthcare Solutions, Inc. | $169 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-22 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-09-20 | Regeneron Healthcare Solutions, Inc. | $446 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Daiichi Sankyo Inc. | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $81 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $33 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $10 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $8 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-09-08 | GENZYME CORPORATION | $37 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-09-05 | Regeneron Healthcare Solutions, Inc. | $5,272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-05 | Regeneron Healthcare Solutions, Inc. | $434 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-05 | Regeneron Healthcare Solutions, Inc. | $181 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-04 | Regeneron Healthcare Solutions, Inc. | $89 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-04 | Daiichi Sankyo Inc. | $14 | Food and Beverage | In-kind items and services | Vanflyta Drug, ONCOLOGY | 2025 | |
| 2025-08-30 | Regeneron Healthcare Solutions, Inc. | $670 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-29 | Regeneron Healthcare Solutions, Inc. | $486 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-22 | Regeneron Healthcare Solutions, Inc. | $1,318 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-15 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-08-08 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-07-29 | Regeneron Healthcare Solutions, Inc. | $691 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-27 | AstraZeneca Pharmaceuticals LP | $53 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-27 | AstraZeneca Pharmaceuticals LP | $47 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-27 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $3,015 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-19 | AstraZeneca Pharmaceuticals LP | $289 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-19 | AstraZeneca Pharmaceuticals LP | $281 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-19 | AstraZeneca Pharmaceuticals LP | $37 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-18 | AstraZeneca Pharmaceuticals LP | $393 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-14 | Genmab U.S., Inc. | $26 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-07-14 | Genmab U.S., Inc. | $20 | Education | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-07-09 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-07-02 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-07-01 | Otsuka America Pharmaceutical, Inc. | $126 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-26 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-06-25 | Daiichi Sankyo Inc. | $670 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $126 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-05-30 | Regeneron Healthcare Solutions, Inc. | $1,318 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-05-30 | Janssen Biotech, Inc. | $1,262 | Consulting Fee | Cash or cash equivalent | ERLEADA Drug, Oncology | 2025 | |
| 2025-05-27 | Janssen Biotech, Inc. | $92 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-05-01 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $124 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-25 | Regeneron Healthcare Solutions, Inc. | $5,272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-25 | Regeneron Healthcare Solutions, Inc. | $968 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-25 | Regeneron Healthcare Solutions, Inc. | $297 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-04-23 | Regeneron Healthcare Solutions, Inc. | $230 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-21 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-04-19 | Regeneron Healthcare Solutions, Inc. | $1,156 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-17 | Dendreon Pharmaceuticals LLC | $34 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-15 | Regeneron Healthcare Solutions, Inc. | $3,954 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-12 | Regeneron Healthcare Solutions, Inc. | $119 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-04 | Daiichi Sankyo Inc. | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-01 | Regeneron Healthcare Solutions, Inc. | $47 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-04-01 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-03-28 | Regeneron Healthcare Solutions, Inc. | $2,636 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-03-27 | Daiichi Sankyo Inc. | $13 | Food and Beverage | In-kind items and services | Vanflyta Drug, ONCOLOGY | 2025 | |
| 2025-03-18 | Regeneron Healthcare Solutions, Inc. | $3,954 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-03-14 | Regeneron Healthcare Solutions, Inc. | $107 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-03-05 | SOBI, INC | $18 | Food and Beverage | In-kind items and services | Doptelet Drug, Hematology/Oncology | 2025 | |
| 2025-02-27 | ARRAY BIOPHARMA INC | $21 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-02-24 | Genentech USA, Inc. | $28 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $50 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $45 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $39 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $9 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $7 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Regeneron Healthcare Solutions, Inc. | $5 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-19 | TerSera Therapeutics LLC | $18 | Food and Beverage | In-kind items and services | Zoladex Drug, Oncology | 2025 | |
| 2025-02-12 | Daiichi Sankyo Inc. | $670 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-02-07 | Regeneron Healthcare Solutions, Inc. | $52 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-07 | Regeneron Healthcare Solutions, Inc. | $44 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-07 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-07 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-07 | Regeneron Healthcare Solutions, Inc. | $9 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-06 | Daiichi Sankyo Inc. | $23 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-02-04 | Regeneron Healthcare Solutions, Inc. | $53 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-04 | Regeneron Healthcare Solutions, Inc. | $48 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-04 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-04 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-02-04 | Celgene Corporation | $14 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-02-04 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-30 | Aveo Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-01-27 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-01-23 | PharmaEssentia USA Corporation | $22 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-01-15 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-01-13 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | Vanflyta Drug, ONCOLOGY | 2025 | |
| 2025-01-10 | Janssen Biotech, Inc. | $33 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-01-09 | Takeda Pharmaceuticals U.S.A., Inc. | $24 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-01-01 | Regeneron Healthcare Solutions, Inc. | $6,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2024-12-21 | Regeneron Healthcare Solutions, Inc. | $530 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-20 | Janssen Biotech, Inc. | $1,350 | Consulting Fee | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2024 | |
| 2024-12-20 | Regeneron Healthcare Solutions, Inc. | $124 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-20 | Janssen Biotech, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2024 | |
| 2024-12-18 | Regeneron Healthcare Solutions, Inc. | $1,524 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-10 | Regeneron Healthcare Solutions, Inc. | $4,605 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-10 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-12-09 | GlaxoSmithKline, LLC. | $2,275 | Consulting Fee | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-12-09 | Daiichi Sankyo Inc. | $1 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-07 | Daiichi Sankyo Inc. | $13 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-07 | Janssen Biotech, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2024 | |
| 2024-12-05 | Astellas Pharma US Inc | $3,425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-12-05 | Astellas Pharma US Inc | $119 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-12-05 | Astellas Pharma US Inc | $32 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-12-05 | Astellas Pharma US Inc | $10 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-11-26 | Daiichi Sankyo Inc. | $150 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-26 | Daiichi Sankyo Inc. | $11 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-26 | Daiichi Sankyo Inc. | $10 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-25 | Eisai Inc. | $31 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-11-22 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | Agios Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-11-18 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-11-14 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-12 | Daiichi Sankyo Inc. | $124 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-11 | Regeneron Healthcare Solutions, Inc. | $154 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-11 | Regeneron Healthcare Solutions, Inc. | $80 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-11 | Regeneron Healthcare Solutions, Inc. | $70 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-11 | Regeneron Healthcare Solutions, Inc. | $36 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-11 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Regeneron Healthcare Solutions, Inc. | $155 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Regeneron Healthcare Solutions, Inc. | $2,456 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Regeneron Healthcare Solutions, Inc. | $217 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Regeneron Healthcare Solutions, Inc. | $137 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Regeneron Healthcare Solutions, Inc. | $38 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Regeneron Healthcare Solutions, Inc. | $5 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-11-04 | Daiichi Sankyo Inc. | $226 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-04 | Daiichi Sankyo Inc. | $18 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-04 | Daiichi Sankyo Inc. | $10 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-01 | Deciphera Pharmaceuticals Inc. | $3,200 | Honoraria | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-11-01 | Deciphera Pharmaceuticals Inc. | $40 | Travel and Lodging | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-11-01 | Deciphera Pharmaceuticals Inc. | $40 | Travel and Lodging | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-10-31 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-31 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-31 | Daiichi Sankyo Inc. | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-29 | Astellas Pharma US Inc | $12 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $607 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $389 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $168 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $74 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $43 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-26 | AstraZeneca Pharmaceuticals LP | $10 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-24 | Regeneron Healthcare Solutions, Inc. | $6,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-24 | Daiichi Sankyo Inc. | $124 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $105 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $66 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $42 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $42 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $40 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $20 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-23 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 |
The latest 200 records of 1,309.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | GENZYME CORPORATION | Profound Research LLC | $2,552 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-12-19 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $10,370 | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi | 2025 |
| 2025-12-02 | GENZYME CORPORATION | Profound Research LLC | $2,904 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-11-20 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $216,111 | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit | 2025 |
| 2025-11-07 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $13,090 | A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Au | 2025 |
| 2025-09-15 | GENZYME CORPORATION | Profound Research LLC | $10,713 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-08-25 | GENZYME CORPORATION | Profound Research LLC | $7,717 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-08-18 | GENZYME CORPORATION | Profound Research LLC | $519 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-07-29 | AstraZeneca Pharmaceuticals LP | Profound Research LLC | $3,000 | a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 in | 2025 |
| 2025-07-28 | GENZYME CORPORATION | Profound Research LLC | $1,000 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-07-21 | GENZYME CORPORATION | Profound Research LLC | $16,303 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-07-02 | GENZYME CORPORATION | Profound Research LLC | $95 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-07-02 | GENZYME CORPORATION | Profound Research LLC | $1,300 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-06-16 | GENZYME CORPORATION | Profound Research LLC | $31,183 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-06-16 | GENZYME CORPORATION | Profound Research LLC | $616 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-05-12 | GENZYME CORPORATION | Profound Research LLC | $968 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-04-14 | GENZYME CORPORATION | Profound Research LLC | $440 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-03-17 | GENZYME CORPORATION | Profound Research LLC | $22,739 | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body | 2025 |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | Profound Research LLC | $28,150 | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilv | 2025 |
| 2025-01-29 | AstraZeneca Pharmaceuticals LP | Profound Research LLC | $110,439 | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig | 2025 |
| 2024-10-11 | AstraZeneca Pharmaceuticals LP | Profound Research LLC | $25,150 | a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 in | 2024 |
| 2024-07-29 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $109,355 | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit | 2024 |
| 2024-07-29 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $21,044 | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi | 2024 |
| 2024-05-15 | Novartis Pharmaceuticals Corporation | Michigan Center Of Medical Research | $22,391 | A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Au | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Dearborn, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Dearborn, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 107,423 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 109,976 | 1,793,561 | 10,077,331 |
| Median age B01002 | 33.3 | 37.9 | 40.2 |
| Under 18 B01001 | 28.7% | 23.6% | 21.2% |
| 65 and over B01001 | 13.7% | 16.6% | 18.6% |
| Households B11001 | 36,695 | 700,591 | 4,076,369 |
| Foreign born B05002 | 30.3% | 10.3% | 7.2% |
| Median household income B19013 | $65,324 | $60,539 | $72,875 |
| Median family income B19113 | $74,152 | $79,522 | $93,357 |
| Per capita income B19301 | $30,588 | $34,906 | $40,735 |
| Poverty rate B17001 | 24.3% | 20.8% | 13.2% |
| Unemployment rate B23025 | 6.6% | 8.7% | 5.7% |
| Civilian labor force B23025 | 45,028 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 21.7 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 34.6% | 27.6% | 32.4% |
| Housing units B25001 | 39,394 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 68.4% | 64.8% | 73.2% |
| Renters B25003 | 31.6% | 35.2% | 26.8% |
| Median home value B25077 | $218,800 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,327 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 87.3% | 47.9% | 72.4% |
| Black B03002 | 3.6% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 2.7% | 6.9% | 5.9% |
| Asian B03002 | 1.8% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dearborn, MI.
Comments